spacer
home > news > detailed info
INDUSTRY NEWS AND PRESS RELEASES

BioGenes Celebrates 25 Years of Excellence in Quality Control of Biotherapeutics

BioGenes GmbH

BioGenes GmbH, specializing in ELISA development and production, is celebrating its 25-year anniversary

Berlin, Germany, July 25, 2017 / B3C newswire/ -- BioGenes GmbH, specializing in ELISA development and production, is celebrating its 25-year anniversary. In 1992 the scientists Dr. Alexander Knoll and Dr. Sergej Ovodov set out with a vision to provide services and kits for the quality control of biotherapeutics. Over the course of the last 25 years, BioGenesís vision has become a reality. BioGenes has grown from a small niche start-up firm providing antibody services to a worldwide leading provider of host cell protein (HCP) assays, customized ELISA development and analytical services.

Company founder and CEO Dr. Alexander Knoll remarked: "This is an incredible milestone for our company. The company has achieved this success through the hard work, passion, and dedication of our team members and our culture of customer service that exists throughout the entire organization. Iím proud to say that our teams consistently exceed client expectations by providing the most efficient, and proactive services to each and every project.Ē

"To this day BioGenes is still driven by the entrepreneurial spirit of our founders, which has enabled us to constantly expand our offering portfolio," said Dagmar Schwertner, Marketing & Sales Director, who has been with the company for 23 years. "In the fall, BioGenes will be launching a new product for immunogenicity testing.Ē As of today, BioGenesí offerings include:

1. Customized ELISA Development
2. Multi-product (platform) and specific HCP assays
3. Generic HCP ELISAs (360-HCP assays for CHO cells and E.coli)
4. Customized Antibodies (incl. anti-idiotypic antibodies)
5. Analytical Services (2D DIGE, 2D Western Blot, HCP coverage determination etc.)

In its 25 years, BioGenes has delivered thousands of projects to our customers. Find out more about BioGenes at www.BioGenes.de
phone +49 (0)30 6576 2396
email service@biogenes.de
web www.biogenes.de
email Koepenicker Str. 325 D-12555 Berlin Germany
 
Print this page
Send to a friend
   
spacer
News and Press Releases

BioGenes Establishes Scientific Advisory Board

Berlin, Germany, December 12, 2017 / B3C newswire / -- BioGenes GmbH, specializing in ELISA development and production and a global leader in host cell protein (HCP) assay development, today announces the establishment of a Scientific Advisory Board which includes the following four renowned experts:
More info >>


White Papers

The Promise and Challenge of Adaptive Design in Oncology Trials

Medpace

Clinical oncology trials are more complex and time consuming than those in any other therapeutic area and failure rates are frustratingly high. Given the urgent need for new oncologic therapies, sponsors are eager to find more effective ways to conduct clinical research. Incorporating adaptive design methodologies into clinical trials can reduce costs and enhance efficiency while maintaining trial integrity. They can also reduce the number of patients on placebo and sub-therapeutic doses. In light of this promise, regulatory bodies have created guidelines supportive of adaptive design.
More info >>

Industry Events

LogiPharma Europe 2018

10-12 April 2018, Montreux Music & Convention Centre

Now in itís 18th successful year, LogiPharma is the largest global end-to-end supply chain event for pharma supply chain leaders, their teams and service partners.
More info >>

 
©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement